Table 2 AJCC 7^th and 8^th edition stagewise treatment outcomes in 630 consecutive patients of OPSCC treated with radiotherapy with or without concurrent chemotherapy.

Stage	5-year LC (%)					5-year LRC (%)					5-year DFS (%)					5-year OS (%)
	All 630	HPV-Negative 445		HPV-Positive 55		All 630	HPV-Negative 445		HPV-Positive 55		All 630	HPV-Negative 445		HPV-Positive 55		All 630	HPV-Negative 445		HPV-Positive 55
Staging System AJCC	7^th	7^th	8^th	7^th	8^th	7^th	7^th	8^th	7^th	8^th	7^th	^7th	8^th	7^th	8^th	7^th	^7th	8^th	7^th	8^th
I	63	63	63	–	95	63	63	63	–	79	54	58	58	–	69	58	63	63	–	68
II	57	52	52	86	76	51	46	46	86	62	34	30	30	69	62	45	46	46	69	60
III	57	54	55	100	79	46	42	43	88	70	43	40	40	78	61	45	45	46	79	69
IVA	44	40	34	77	–	29	27	25	61	–	23	21	19	54	–	28	25	23	61	–
IVB	40	21	46	89	–	25	10	25	78	–	25	13	22	79	–	31	17	27	89	–

AJCC The American Joint Committee on Cancer, ed Edition, LC Local Control, LRC Locoregional control, DFS Disease Free Survival, OS Overall Survival.

Quick links

Search